SRR934820
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 34.39553219448094
- age_years
- 46
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.443
- MITOTIC_SPINDLE+0.424
- PROTEIN_SECRETION+0.401
- ANDROGEN_RESPONSE+0.358
- G2M_CHECKPOINT+0.333
- WNT_BETA_CATENIN_SIGNALING+0.322
- MYC_TARGETS_V1+0.298
- CHOLESTEROL_HOMEOSTASIS+0.274
- NOTCH_SIGNALING+0.272
- UNFOLDED_PROTEIN_RESPONSE+0.255
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.433
- KRAS_SIGNALING_DN-0.339
- INTERFERON_ALPHA_RESPONSE-0.264
- MYOGENESIS-0.248
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.247
- INTERFERON_GAMMA_RESPONSE-0.236
- ALLOGRAFT_REJECTION-0.234
- SPERMATOGENESIS-0.197
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.162
- ANGIOGENESIS-0.144
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | D5E8379B-621C-4551-9B13-E63B1B068488 | — | — | 0.888 |
| 2 | SRR934758 | — | — | 0.884 |
| 3 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.864 |
| 4 | F35F85A8-B3CD-4116-990F-94B2E432F902 | — | — | 0.864 |
| 5 | 4A4E96B0-5AC6-4B7D-AB1C-F814C338589C | — | — | 0.858 |
| 6 | MNG666 | — | — | 0.856 |
| 7 | 6990AABF-A5F4-4784-91FF-286A0EE6A618 | — | — | 0.853 |
| 8 | SRR934725 | — | — | 0.851 |
| 9 | SRR934969 | — | — | 0.850 |
| 10 | SRR934870 | — | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.443 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.424 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.401 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.358 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.333 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.322 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.298 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.274 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.272 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.255 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.231 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.225 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.219 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.218 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.207 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.191 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.188 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.186 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.185 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.152 | Idelalisib | — uncovered |